You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201481 - 201490 of 207728 results
  1. Magnetic Resonance Imaging Subsystem for Cardiac Ischemia Evaluation

    SBC: HeartVista, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cardiac magnetic resonance imaging (MRI) has been shown to be one of the best technologies for the evaluation of cardiovascular pathologies. The broad application of this promising technology is expected to significantly improve the treatment of patients with heart disease in general and ischemic heart diseases in particular. However, widespread adoption of th ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A Flow Through Cell Counting Assay

    SBC: ALLIED INNOVATIVE SYSTEMS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The long-term goal of the proposed research is to develop a novel quantitative flow through cell counting method for enumeration of CD4+ T lymphocytes in human blood. CD4 cell counts are needed to stage and monitor HIV-infected patients. In adults, the absolute number of CD4+ T cells per microlitre of blood has critical prognostic and therapeutic implications, ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Improved Adventitial Rapamycin Therapy for Peripheral Artery Restenosis

    SBC: MERCATOR MEDSYSTEMS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Peripheral artery disease (PAD) affects 9 to 12 million Americans [1] and 1.5 million will require an intervention (407,400 receive bypass or amputation; 1,080,000 receive angioplasty, stent or atherectomy) each year [3]. Unfortunately, only one-third of patients have a patent artery one year after balloon angioplasty of the femoral artery [4]. Bare metal sten ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid, Near-Tranfusion Test for Bacteria in Platelets Units

    SBC: IMMUNETICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Bacterial contamination of platelets is considered the greatest infectious risk of blood product transfusion today at about 1 in 2000 platelet units, which is several orders of magnitude greater than that of HIV. Bacterial contamination at high levels can lead to severe morbidity or mortality in transfusion recipients. The American Association of Blood Banks is ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Development of transapical MVAD for heart failure therapy

    SBC: HEARTWORKS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this proposal is to complete engineering development and pre-clinical testing of a transapical miniaturized ventricular assist device (tMVAD) to treat patients with less advanced heart failure (HF). HFis increasing worldwide and represents a major burden in terms of health care resources and costs. Despite advances in medical care, prognosis wi ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a point of care diagnostic to guide efficient usage of blood produ

    SBC: HEMOSONICS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The Problem: Over 60% of the 600,000 patients undergoing cardio-pulmonary bypass (CPB) procedures in the US each year experience excessive bleeding, which requires transfusions of blood products. There are four treatment options available, each corresponding to a specific hemostatic defect: (a) fresh frozen plasma (FFP) to correct the plasma coagulation factors ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Organocatalysis for the treatment of sickle cell disease

    SBC: NANOMETICS LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a global health issue that affects ~100,000 Americans and over 13 million people worldwide. The complexity of the disease dictates that a multimodal approach to treatment will likely be needed. SCD is manifested physiologically during acute events of sickle crisis as the distorted red blood cells impede blood flow, causing physiolog ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Correlating TCR diversity to immune reconstitution after cord blood transplant

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants using stem cells from umbilical cord blood provide an alternative for these patients, allowing transplantation to proceed with less stringent HLA-matching requirements. Unfortunately, in addition to t ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Novel, Long-Term Percutaneous Access Device for Chronic Therapy

    SBC: VIADERM, LLC            Topic: NHLBI

    DESCRIPTION: A novel, next-generation percutaneous access device (PAD) focused on pre-emptively reducing catheter related exit site infection will be developed for the delivery of chronic, life-sustaining therapies requiring long- term access through theskin. ViaDerm II uses vacuum assist to remove exudate and proliferate dermal fibroblasts as soon as the catheter penetrates the skin. In additio ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Bifunctional Redox Catalyst and Organic Nitrate for Limb Reperfusion

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute limb ischemia reperfusion injury (LIRI) is characterized by an imbalance in the free radicals nitric oxide and superoxide anion. Accordingly, replenishment of nitric oxide and removal of superoxide are each partially effective, but greater protection of muscle injury is expected from the simultaneous correction of both abnormalities. To address this unmet ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government